Integral characteristic of the immune system state predicts breast cancer outcome
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-1.12593Keywords:
breast cancer, cancer outcome, cancer prognosis, immune system.Abstract
Summary. The immune system dramatically contributes to the pathogenesis of cancer. An integral estimation of immune system state is considered to be perspective as a prognostic criterion for cancer. We hypothesize that the integral characteristic, uniting numerous parameters of immune response to tumor and presenting the state of the immune system of a cancer patient, may be of prognostic significance. The aim of this work was to verify this hypothesis. Materials and Methods: We have evaluated 17 parameters characterizing key innate and adaptive arms of immune system in 146 patients with primary diagnosed local breast cancer (BC) before cancer treatment. Using the original integrative approach of NovoSpark Corporation (Canada), we have presented the state of the immune system by a single visual image for each patient. Results: We classified all BC patients in two groups: with favorable and unfavorable immune system states according to our previous data demonstrating dramatic differences of the visual images of immune system states in patients with good or poor disease outcomes. Then, we have examined the relationship between integral characteristic of the immune system state and the clinical outcome. The 3-year disease-free survival (DFS) of BC patients with favorable immune system state was more than 96.0% vs 65.4% in patients with unfavorable status (p = 0.00006). Univariate Cox proportional hazards regression analysis showed that the integral characteristic of immune system state assessed prior to cancer treatment as unfavorable, was predictive of the poorer DFS (HR = 15.70 [2.15–114.90], p = 0.0007). Conclusion: The integral characteristic of the immune system state is a significant prognostic factor in BC patients. The BC patients with favorable integral immune system state can be considered as a target group for immunotherapeutic approach.
References
Colleoni M, Viale G, Goldhirsch A. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast 2009; 18: S137–S40.
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206–23.
Campbell HE, Epstein D, Bloomfield D, et al. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer 2011; 47: 2517–30.
Mei ZB, Shi L, Wang B, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. Cancer Treatment Rev 2017; 58: 1–13.
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869–74.
Oakman C, Bessi S, Zafarana E, et al. Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009; 11: 205.
Rodenhiser DI, Andrews JD, Vandenberg TA, et al. Gene signatures of breast cancer progression and metastasis. Breast Cancer Res 2011; 13: 201.
Saraiva DP, Cabral MG, Jacinto A, et al. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. Esmo Open 2017; 2: e000208.
Imai H, Kuroi K, Ohsumi S, et al. Economic evaluation of the prevention and treatment of breast cancer-present status and open issues. Breast Cancer 2007; 14: 81–7.
Gramatyka M. Cardiotoxicity as undesired side effect in the treatment of breast cancer. Postepy Higieny I Medycyny Doswiadczalnej 2014; 68: 483–97 (in Polish).
Chen XG, Li JJ, Ren J, et al. Selective impairment of attention networks in breast cancer patients receiving chemotherapy treatment. Psycho-Oncology 2014; 23: 1165–71.
Hansen RN, Ramsey SD, Lalla D, et al. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus 2014; 3: 259.
Zitvogel L, Kepp O, Aymeric L, et al. Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res 2010; 70: 9538–43.
Cavallo F, De Giovanni C, Nanni P, et al. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011; 60: 319-26.
Bachireddy P, Rakhra K, Felsher DW. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clin Exp Immunol 2012; 167: 188–94.
Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14: E218–28.
Whiteside TL. Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol 2013; 3: 1–8.
Whiteside TL, Demaria S, Rodriguez-Ruiz ME, et al. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res 2016; 22: 1845–55.
Al-Shibli K, Al-Saad S, Andersen S, et al. The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma. APMIS 2010; 118: 371–82.
Suzuki K, Kachala SS, Kadota K, et al. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011; 17: 5247–56.
Faria SS, Fernandes PC, Silva MJB, et al. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancer 2016; 10: 702.
Matsueda S, Komatsu N, Kusumoto K, et al. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases. DCI 2013; 41: 68–76.
Shang B, Liu Y, Jiang SJ. Prognostic value of tumor-infiltrating FoxP3(+) regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015; 5: 15179.
Shou JF, Zhang ZG, Lai YC, et al. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic review and meta-analysis. BMC Cancer 2016; 16: 687.
Park IH, Kong SY, Ro JY, et al. Prognostic implications of tumor-infiltrating lymphocytes in association with programmed death ligand 1 expression in early-stage breast cancer. Clin Breast Cancer 2016; 16: 51–8.
Mlecnik B, Bindea G, Pages F, et al. Tumor immunosurveillance in human cancers. Cancer Metastas Rev 2011; 30: 5–12.
Ascierto ML, De Giorgi V, Liu QZ, et al. An immunologic portrait of cancer. J Transl Med 2011; 9: 146.
Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10: 1.
Galon J, Angell HK, Bedognetti D, et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39: 11–26.
Demicheli R, Retsky MW, Hrushesky WJM, et al. The effects of surgery on tumor growth: a century of investigations. Ann Oncol 2008; 19: 1821–8.
Hanin L. Why victory in the war on cancer remains elusive: biomedical hypotheses and mathematical models. Cancers (Basel) 2011; 3: 340–67.
Meng XL, Zhong J, Liu SY, et al. A new hypothesis for the cancer mechanism. Cancer Metastas Rev 2012; 31: 247–68.
Nicholson LB. The immune system. Essays Biochem 2016; 60: 275–301.
Marques RE, Marques PE, Guabiraba R, et al. Exploring the homeostatic and sensory roles of the immune system. Front Immunol 2016; 7: 125.
Holtan SG, Dronca RS, Nevala WK, et al. The dynamic human immune response to cancer: it might just be rocket science. Immunotherapy 2011; 3: 1021–4.
Dronca RS, Leontovich AA, Nevala WK, et al. Personalized therapy for metastatic melanoma: could timing be everything? Future Oncol 2012; 8: 1401–6.
Leontovich A, Dronca R, Suman V, et al. Fluctuation of systemic immunity in melanoma and implications for timingof therapy. Front Biosci (Elite Ed) 2012; 1: 958–75.
Stakheyeva MN, Serykh AP, Karas SI, et al. The complex of informative immunological parameters for breast cancer outcome prognosis. Bull Sib Med 2015; 14: 30–4.
Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011; 9: 13.
Tsang JS, Schwartzberg PL, Kotliarov Y, et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 2014; 157: 499–513.
Brodin P, Jojic V, Gao TX, et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 2015; 160: 37–47.
Eldenzon D, Shamroni D, Volovodenko V. Method and system for multidimensional data visualization. Saarbrucken: LAP LAMBERT Acad Publ, 2013. 45 p.
Stakheyeva M, Eidenzon D, Cherdyntseva N, et al. Multidimensional visualization for the immune system state presentation in breast cancer patients. 5th Int Sci Conf on New Operational Technologies (NEWOT); 2015 Sep 29–30; Tomsk, Russia 2015.
Stakheyeva M, Eidenzon D, Cherdyntseva N, et al. Inventors method for predicting hematogenous metastasis in patients with breast cancer during antitumor treatment. Patent of Russian Federation, 2011 (in Russian).
Totolian AA, Baldueva IA, Bubnova LN, et al. Standartization of immunophenotyping methods of human blood and bone marrow cells. Part III. Immunochemistry method. Part IV. Normal values. Clin Lab Diagnost 2002; (1): 44–50.
Nesterova IV, Kolesnikova NV, Simbirtsev AS, et al. Influence of long-time administration of syntetic dipeptide on neutrophile function in vivo. Immunologia 1999; (6): 40–6.
Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Inv 2007; 117: 1137–46.
Capra F. The systems view of life a unifying conception of mind, matter, and life. Cosmos and History. J Nat Social Philosophy 2015; 11: 242–9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
